# Glenmark Pharmaceuticals Limited - Inspection Records

Source: https://www.globalkeysolutions.net/companies/glenmark-pharmaceuticals-limited/66c964bb-f670-493b-ab86-aa8507e68a5d

> Inspection records and compliance data for Glenmark Pharmaceuticals Limited in Solan, None. Access full analysis and detailed observations.

---

## Details

- Name: Glenmark Pharmaceuticals Limited
- FEI Number: 3005757050
- City: Solan
- State: None
- Country Name: India
- Address Line 1: Village Kishanpura, Baddi Nalagarh Road, Baddi
- Zip Code: None
- Business Operations: API/FDF ANALYTICAL TESTING, FDF MANUFACTURE, PACK

## Related Documents

- [483 - Glenmark Pharmaceuticals Limited - 2022-06-22](https://www.globalkeysolutions.net/records/483/glenmark-pharmaceuticals-limited/bbfcf848-0ee0-45ac-a30f-6b77a402de44) — source: FDA, date: June 22, 2022
- [FDA Inspection 1172425 - Glenmark Pharmaceuticals Limited - 2022-06-22](https://www.globalkeysolutions.net/records/fda_inspections/glenmark-pharmaceuticals-limited/84dfdb76-1ec3-4ae9-a550-4882585f55ac) — classification: Official Action Indicated (OAI), source: FDA, date: June 22, 2022
- [WARNING_LETTER - Glenmark Pharmaceuticals Limited - 2022-05-20](https://www.globalkeysolutions.net/records/warning_letter/glenmark-pharmaceuticals-limited/0ac1907c-5a77-4f23-8229-957f8b7079ca) — source: FDA, date: May 20, 2022
- [483 - Glenmark Pharmaceuticals Limited - 2019-04-20](https://www.globalkeysolutions.net/records/483/glenmark-pharmaceuticals-limited/b7ff58c7-f479-4ebb-a95a-ce9b1c103a62) — source: FDA, date: April 20, 2019
- [WARNING_LETTER - Glenmark Pharmaceuticals Limited - 2019-04-20](https://www.globalkeysolutions.net/records/warning_letter/glenmark-pharmaceuticals-limited/564e19c0-f3be-4691-97d4-7b89ca5fceb2) — source: FDA, date: April 20, 2019
- [FDA Inspection 1070594 - Glenmark Pharmaceuticals Limited - 2018-09-21](https://www.globalkeysolutions.net/records/fda_inspections/glenmark-pharmaceuticals-limited/6461db84-7c7a-4c1a-82dd-e10fbf5610e4) — classification: No Action Indicated (NAI), source: FDA, date: September 21, 2018
- [483 - Glenmark Pharmaceuticals Limited - 2017-11-11](https://www.globalkeysolutions.net/records/483/glenmark-pharmaceuticals-limited/da1521e9-2291-4a93-9ea2-3fdff9b7facf) — source: FDA, date: November 11, 2017
- [FDA Inspection 1031652 - Glenmark Pharmaceuticals Limited - 2017-11-11](https://www.globalkeysolutions.net/records/fda_inspections/glenmark-pharmaceuticals-limited/9dbf23a8-439d-4a57-bd29-3319b9215d79) — classification: Voluntary Action Indicated (VAI), source: FDA, date: November 11, 2017
- [FDA Inspection 929619 - Glenmark Pharmaceuticals Limited - 2015-05-29](https://www.globalkeysolutions.net/records/fda_inspections/glenmark-pharmaceuticals-limited/e5a82147-ec6f-492c-83d4-281cf15f8b12) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 29, 2015
- [FDA Inspection 802324 - Glenmark Pharmaceuticals Limited - 2012-08-24](https://www.globalkeysolutions.net/records/fda_inspections/glenmark-pharmaceuticals-limited/83d0df5c-715d-40c8-a9d8-a5f36632ac2a) — classification: No Action Indicated (NAI), source: FDA, date: August 24, 2012
- [FDA Inspection 643147 - Glenmark Pharmaceuticals Limited - 2009-11-13](https://www.globalkeysolutions.net/records/fda_inspections/glenmark-pharmaceuticals-limited/c66b0396-b96a-436c-95a0-408e519111a8) — classification: Voluntary Action Indicated (VAI), source: FDA, date: November 13, 2009

## Related Companies

- [MassBiologics](https://www.globalkeysolutions.net/companies/massbiologics/fa584e7c-22de-470c-836a-dd3028fae600)
- [Catalent Belgium SA](https://www.globalkeysolutions.net/companies/catalent-belgium-sa/f48653bf-84a2-4aeb-bdc3-ca2d0cc4fdf2)
- [Gland Pharma Limited, Units I+II Pashamylaram Site](https://www.globalkeysolutions.net/companies/gland-pharma-limited-units-iii-pashamylaram-site/a7dffca3-c5cc-4802-9cab-54995e7133ca)
- [Dendreon Pharmaceuticals LLC](https://www.globalkeysolutions.net/companies/dendreon-pharmaceuticals-llc/3de4a8e5-8e34-4212-8862-ecd5256c6ffe)
- [Ipca Laboratories Limited](https://www.globalkeysolutions.net/companies/ipca-laboratories-limited/8357cd13-53b4-4e4d-a2a5-54b750096c7a)
- [NATCO Pharma Limited](https://www.globalkeysolutions.net/companies/natco-pharma-limited/4c97e2d8-0023-4572-966f-d396e8fecc05)
- [Novartis Pharmaceuticals Corporation](https://www.globalkeysolutions.net/companies/novartis-pharmaceuticals-corporation/21559fd5-35ed-4cbd-b228-623dd76bcf47)
- [Ipca Laboratories Limited](https://www.globalkeysolutions.net/companies/ipca-laboratories-limited/4221e8f5-a261-45fc-b9fc-d935bc1f225b)
- [Recipharm Monts](https://www.globalkeysolutions.net/companies/recipharm-monts/e3b2f0c3-26eb-4020-8127-76127e9e18d6)
- [Kite Pharma, Inc.](https://www.globalkeysolutions.net/companies/kite-pharma-inc/5bf88060-db53-466b-9a1c-85be7984894f)

## Related Officers

- [Jogy George](https://www.globalkeysolutions.net/people/jogy-george/00ef0915-66d2-4b34-9b74-d1e08caf2db3)
- [Dipesh K. Shah](https://www.globalkeysolutions.net/people/dipesh-k-shah/d4df4040-13d1-477b-8c21-4c8e5b3fc5b9)
- [Research Specialist II](https://www.globalkeysolutions.net/people/justin-a-boyd/796c9c9d-02db-486c-bdca-cc259066a0e2)
- [Rita Kabaso](https://www.globalkeysolutions.net/people/rita-kabaso/a8383d6d-b945-4edc-97a4-90944574835d)
- [Director](https://www.globalkeysolutions.net/people/francis-godwin/1556d203-d47c-4744-af37-2591a163149e)